Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
Recruiting · NCT07256015 · Observational (researchers observe without assigning treatment) · Lead sponsor: Bristol-Myers Squibb
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Participants have initiated treatment with deucravacitinib monotherapy 4 to 8 weeks earlier according to clinical practice and to reimbursement criteria determined by National Drug Agency in Italy (AIFA)
- Patients have moderate to severe plaque psoriasis
- Patients have signed informed consent form (ICF)
Exclusion criteria
- Simultaneous participation in any interventional study for their moderate-to-severe psoriasis
- Inability to participate to the study for the following reasons: patients unable to understand the aim of the study, patients unable to understand and sign the ICF
Where it is running
1 location listed.
- Azienda Ospedaliera Universitaria Integrata Di Verona - Verona, Verona, Italy